MedPath

Hydrogen inhalation therapy for head and neck cancer patients

Phase 2
Conditions
Health Condition 1: C760- Malignant neoplasm of head, face and neck
Registration Number
CTRI/2023/03/051034
Lead Sponsor
Harshamitra superspeciality cancer center and research institute
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.All patients with primary head and neck cancer treated with concurrent chemo radiation between February 2023 to February 2024

2.Patients belonging to all age groups, both male and females were included

Exclusion Criteria

1. Patients with Stage IV disease

2.Patients receiving palliative radiation

3.Patients with recurrent head and neck cancers on re radiation

4.Immune compromised patients and those with auto immune diseases.

5.Patients with any other disease or condition that may add to the toxicity

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath